Answers are grounded in this paper and cite their sources.
Benin (10 of 325 samples [3.1%]), and Congo-Brazzaville (10 of 150 samples [6.7%]).Discussion | To our knowledge, we have presented the first data on the quality of cardiovascular drugs in countries in sub-Saharan Africa.We found a high prevalence of poor-quality drugs, with a little less than 1 in 6 samples failing to meet standards.The observed variation in quality by country merits consideration.Indeed, in 2013, operation BIYELA was carried out in 23 African countries and resulted in the interception of more than 500 million illicit or falsified drugs, most of which were from Benin, Tanzania, and the Democratic Republic of the Congo. 6 Conclusions | A combination of political apathy and corruption may make the task of improving the quality of drugs especially challenging in the developing world.Increasing public awareness and heightening international scrutiny are necessary to bring about changes.Improving the quality of cardiovascular drugs would be a major achievement for the prevention and control of noncommunicable diseases in sub-Saharan Africa.Improvement in the public's access to effective medications also remains an important goal that will help to achieve the target of the United Nations of a 25% reduction in premature cardiovascular disease mortality by 2025. 7Accessibility to quality drug testing for interested parties is a crucial requirement.
No takes yet. Share an insight, caveat, or question.
Antignac et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: